Therapeutic Exploratory (Phase II)

3,454 trials 1,368 recruiting

Filter these 3,454 trials by condition, country, sponsor and more.

Open in Search →

SMART-MS Recruiting

2023-510228-63-00 Multiple sclerosis 2024-05-01
Precision Medicine in patients with unresectable CholAngiocarcinoma; RadioEmbolization and combined biological therapy (PM-CARE). Single arm… Recruiting

2024-516498-57-00 liver predominant intrahepatic cholangiocarcinoma 2024-04-30
A Study to Investigate the Pharmacokinetics (PK) and Safety of Risdiplam in Infants with Spinal Muscular Atrophy Recruiting

2023-505602-42-00 Spinal Muscular Atrophy (SMA) 2024-04-30
Sbrt±sTad for Unfavorable iNtermediate rIsk/high-risk prostate cancer (STUNNIN): A Randomized Phase II Study Recruiting

2024-511886-12-00 Unfavorable intermediate/high risk prostate cancer pati 2024-04-29
Dapagliflozin in patients with Right Heart Failure (Dapa-RHF) Recruiting

2024-515044-23-01 Chronic right heart failure 2024-04-29
UVB: treatment of UVeitis in Behçet’s diseases with biologic Recruiting

2024-513371-41-00 Severe uveitis of Behçet’s disease 2024-04-25
A novel COMBinATorial therapy with albumin and enoxaparin in patients with decompensated cirrhosis at high-risk of poor outcome (COMBAT tria… Recruiting

2023-507073-18-00 Cirrhosis 2024-04-24
Examining the impact of propranolol on preoperative anxiety and on tumorigenic changes in patients with pancreatic ductal adenocarcinomas: a… Recruiting

2023-506553-37-00 Pancreatic ductal adenocarcinoma (PDAC) 2024-04-23
Psilocybin for hospitalized patients with treatment-resistant depression Recruiting

2022-501857-35-00 treatment-resistant depression 2024-04-22
Evaluation of the efficacy and safety of Rituximab in patients with Amyotrophic Lateral Sclerosis (ALS) Recruiting

2022-502743-35-00 Sporadic Amyotrophic Lateral Sclerosis 2024-04-22
Study to compare the activation of the immune system depending on the chemotherapy scheme used together with PEMBROLIZUM (immunotherapy) in … Recruiting

2023-507008-30-00 High risk (TILs-positive) HR-/HER2- (triple negative) b 2024-04-17
Multi-cohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia TAILOR Recruiting

2023-504044-34-00 Untreated Chronic Lymphocytic Leukemia 2024-04-17
Study of GS-5290 in Participants With Moderately to Severely Active Ulcerative Colitis Recruiting

2022-501119-14-01 Ulcerative Colitis 2024-04-16
Gut microbiome intervention with EXL01 in combination with nivolumab and FOLFOX as first-line treatment for patients with PD-L1 CPS ≥5 metas… Recruiting

2023-506753-38-00 metastatic gastric adenocarcinoma 2024-04-16
PACCELIO - FDG-PET based small volume accelerated immuno chemoradio-therapy in locally advanced NSCLC Recruiting

2023-510506-41-00 Locally advanced, unresectable non-small-cell lung canc 2024-04-15
COMBAT-ARF Recruiting

2024-512641-16-00 Infectious pulmonary endotheliopathy 2024-04-15
Clinical study to assess the efficacy and safety of Cannabidiol in children and young adults with rare disease-associated severe epilepsy Recruiting

2023-503709-12-00 Epilepsy 2024-04-12
A randomised phase II placebo-controlled trial of ART plus dual long-acting HIV-specific broadly neutralising antibodies (bNAbs) vs ART plus… Recruiting

2024-516150-22-00 HIV 2024-04-11
A Placebo-controlled Study to Evaluate the Efficacy and Safety of Clenbuterol in Patients with Spinal and Bulbar Muscular Atrophy (SBMA) Recruiting

2024-516563-86-00 Spinal and Bulbar Muscular Atrophy 2024-04-11
European Larynx Organ Preservation Study (ELOS) Recruiting

2022-502751-61-00 Advanced stage III, IVA, IVB laryngeal or II, III, IVA, 2024-04-10
Efficacy and Safety of cangrelor on top of anticoagUlation in patients with myocaRdial infarction related cardiogenic shock/cardiac arrest r… Recruiting

2024-512829-81-00 Adult patients treated in VA ECMO/Impella for cardiogen 2024-04-10
PRIDE – PRotective VEGF Inhibition for Isotoxic Dose Escalation in Glioblastoma Recruiting

2024-514865-20-00 Glioblastoma 2024-04-10
Sleep and body temperature as markers of progression of Alzheimer's disease in Down syndrome. Recruiting

2023-506609-21-00 Down Syndrome. 2024-04-09
A multicenter uncontrolled, open label, prospective non-comparative single arm phase II study with bicalutamide (an antiandrogen) in combina… Recruiting

2022-502272-23-00 Locally advanced unresectable or metastatic androgen re 2024-04-08